Stuart D Rosen
Overview
Explore the profile of Stuart D Rosen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cleary S, Rosen S, Gilbert D, Langley R
BMJ Oncol
. 2025 Jan;
2(1):e000090.
PMID: 39886493
Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals...
2.
Tayal U, Pompei G, Wilkinson I, Adamson D, Sinha A, Hildick-Smith D, et al.
Heart
. 2024 Sep;
110(22):e4.
PMID: 39317437
Despite significant progress in cardiovascular pharmacotherapy and interventional strategies, cardiovascular disease (CVD), in particular ischaemic heart disease, remains the leading cause of morbidity and mortality among women in the UK...
3.
Senechal I, Andres M, Tong J, Ramalingam S, Nazir M, Rosen S, et al.
Curr Oncol Rep
. 2024 Sep;
26(11):1431-1441.
PMID: 39316222
Purpose Of Review: In this review article we describe the cardiovascular adverse events associated with BRAF and MEK inhibitors as well as their pathophysiologic mechanisms and provide up to date...
4.
Tong J, Vogiatzakis N, Andres M, Senechal I, Badr A, Ramalingam S, et al.
Cardiooncology
. 2024 Aug;
10(1):53.
PMID: 39175028
Background: Immune checkpoint inhibitor (ICI) myocarditis is an uncommon but potentially fatal complication of immunotherapy. Cardiac imaging is essential to make timely diagnoses as there are critical downstream implications for...
5.
Fernando F, Andres M, Claudiani S, Kermani N, Ceccarelli G, Innes A, et al.
Cardiooncology
. 2024 Jul;
10(1):42.
PMID: 39010172
Background: The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associated with...
6.
Andres M, Murphy T, Poku N, Nazir M, Ramalingam S, Baksi J, et al.
JACC CardioOncol
. 2024 May;
6(2):310-312.
PMID: 38774020
No abstract available.
7.
8.
Senechal I, Vogiatzakis N, Andres M, Tong J, Ramalingam S, Rosen S, et al.
Cardiooncology
. 2024 Apr;
10(1):23.
PMID: 38605419
Panitumumab is a human immunoglobulin monoclonal antibody designed to target the epidermal growth factor receptor (EGFR) which is used in the treatment of metastatic colorectal cancer alone or in combination...
9.
Senechal I, Andres M, Tong J, Perone Y, Ramalingam S, Nazir M, et al.
Cardiooncology
. 2024 Mar;
10(1):14.
PMID: 38454509
Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted...
10.
Nazir M, Okafor J, Murphy T, Andres M, Ramalingham S, Rosen S, et al.
Radiol Cardiothorac Imaging
. 2024 Feb;
6(1):e249003.
PMID: 38358331
No abstract available.